EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis

Timothy Arthur Chandos Snow iD, Walter Pisciotta, Gladys Martir, Caroline Copeland iD, Athanasios Sekeris, Abhishek Das, Mervyn Singer iD, David Brealey, Nishkantha Arulkumaran

Journal of Leukocyte Biology · 08.06.2026 · 118 (6)

DOI: 10.1093/jleuko/qiag057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 30.06.2026. Verfasst von Timothy Arthur Chandos Snow und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, Gower Street, London, WC1E 6BT, United Kingdom. Hauptthemen laut MEDLINE: Interleukin-7, Sepsis, Nivolumab, Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, RCoA/BJA Project Award, University College London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic modulation of sepsis-induced immune dysfunction by targeting lymphocyte dysfunction with recombinant IL-7 (rIL-7) and anti-PD-1 (e.g. nivolumab) has shown promise in preclinical and early clinical studies. Prior to conducting large randomized controlled trials, an in-depth understanding of the changes induced by rIL-7 or nivolumab (and their differences) in patients with sepsis is imperative. We performed a prospective observational cohort study including patients admitted to the intensive care unit with sepsis and characterized their T lymphocyte phenotype using flow cytometry. The ability of T lymphocytes to respond to a stimulus (using anti-CD3/CD28 beads) and the effect of rIL-7 or nivolumab on T lymphocyte immunophenotype ex vivo was assessed. In a cohort of 55 patients, CD4+ and CD8+ T lymphocyte PD-1 was higher and IL-7R lower compared with healthy volunteers. In a subset of 24 intensive care unit patients in whom in-depth immunophenotype was characterized, ex vivo response of lymphocytes to anti-CD3/CD28 beads was reduced compared with healthy volunteers, simultaneously inducing features consistent with immune activation and immunosuppression. rIL-7 was associated with a greater spectrum of changes compared with nivolumab. The response to rIL-7 and nivolumab was influenced by anti-CD3/CD28 bead costimulation. rIL-7 and nivolumab elicited distinct T lymphocyte responses ex vivo, and the changes were influenced by T lymphocyte activation. It needs to be determined if similar changes occur in vivo, which may influence the choice of immunomodulatory therapy in sepsis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-7SepsisNivolumabLymphocytesHumansMaleFemaleMiddle AgedAgedRecombinant ProteinsProspective StudiesLymphocyte ActivationImmunophenotyping

Stichwörter der Autor:innen

immunomodulationinfectionlymphocyteproliferationsepsis

Substanzen

Interleukin-7NivolumabRecombinant ProteinsIL7 protein, human

Autor:innen und Institutionen

  • Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, Gower Street, London, WC1E 6BT, United Kingdom.
  • Centre for Anaesthesia, Critical Care & Pain Medicine, Department of Targeted Intervention, University College London, Gower Street, London, WC1E 6BT, United Kingdom.
  • Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, Strand, London, WC2R 2LS, United Kingdom.
  • Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT, United Kingdom.
  • UCLH NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, Euston Road, London, NW1 2BU, United Kingdom.

ORCID-Profile: Timothy Arthur Chandos Snow, Caroline Copeland, Mervyn Singer

Förderung

  • UK Medical Research Council
  • RCoA/BJA Project Award
  • University College London
  • European Society of Intensive Care Medicine
  • UCLH NIHR Biomedical Research Centre

Zitieren

APA

Snow, T. A. C., Pisciotta, W., Martir, G., Copeland, C., Sekeris, A., Das, A., Singer, M., Brealey, D., & Arulkumaran, N. (2026). Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis. Journal of Leukocyte Biology, 118(6). https://doi.org/10.1093/jleuko/qiag057

Vancouver

Snow TAC, Pisciotta W, Martir G, Copeland C, Sekeris A, Das A, et al. Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis. Journal of Leukocyte Biology. 2026;118(6). doi:10.1093/jleuko/qiag057

BibTeX
@article{Snow2026,
  author = {Snow, Timothy Arthur Chandos and Pisciotta, Walter and Martir, Gladys and Copeland, Caroline and Sekeris, Athanasios and Das, Abhishek and Singer, Mervyn and Brealey, David and Arulkumaran, Nishkantha},
  title = {Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis},
  journal = {Journal of Leukocyte Biology},
  year = {2026},
  volume = {118},
  number = {6},
  doi = {10.1093/jleuko/qiag057}
}
Kostenlos starten →